Structured evidence table for Saffron Cognitive Performance Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Saffron Cognitive Performance Meta-Analysis | In general, risk of bias in selective reporting and incomplete data were low, and bias regarding inclusion of intention-to-treat analysis was low to moderate. | 1 | Ho Chao-Yen (2026) | Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis of randomized-controlled trials |
| Saffron Cognitive Performance Meta-Analysis | The analysis revealed a pooled SMD (pSMD) = 1.20 (95 % confidence interval [CI]: 0.64 to 1.76), indicating that taking herbal dietary supplements was associated with a greater improvement in erectile function as compared to controls. | 1 | Ho Chao-Yen (2026) | Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis of randomized-controlled trials |
| Saffron Cognitive Performance Meta-Analysis | Saffron (pSMD = 2.23, 95 % CI: 1.66 to 2.80) and ginseng (pSMD = 0.41, 95 % CI: 0.20 to 0.62) were each significantly associated with greater improvement in ED compared to that of controls, whereaswas shown to have positive effects on ED compared to controls, but the difference was not statistically significant (pSMD = 0.74, 95 % CI: −0.24 to 1.72). | 1 | Ho Chao-Yen (2026) | Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis of randomized-controlled trials |
| Saffron Cognitive Performance Meta-Analysis | Incidence of ED is reported to increase with increasing age.An estimated 8.3 % of insured men in the United States have been diagnosed with ED, translating to approximately 10.3 million men seeking care for this condition as of 2022. | 1 | Ho Chao-Yen (2026) | Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis of randomized-controlled trials |
| Saffron Cognitive Performance Meta-Analysis | In recent years, a growing body of scientific evidence supporting several of these traditional uses has shown the potential of saffron and its main ingredients—crocins, crocetin, safranal, and picrocrocin—as pharmacologically relevant compounds. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Meta-Analysis | By integrating evidence from in vitro studies, animal models, and clinical trials, this review critically assesses saffron’s potential as a multi-target pharmacological agent and identifies key limitations and future directions for its development within pharmaceutical and integrative medicine frameworks. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Meta-Analysis | Considering the scope of disease areas covered, this review is intended to be a broad narrative overview rather than an exhaustive systematic evaluation of each disease, with a focus on critically evaluating study quality, level of evidence, gaps between preclinical findings and clinical applicability, and limitations across sections. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
| Saffron Cognitive Performance Meta-Analysis | Crocus sativus 1 2 3 4 5 6 Natural products remain one of the main sources of pharmacologically bioactive compounds (BACs) and have played a fundamental role in the development of new drugs. | 3 | Campos Catarina (2026) | From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases |
Source documents